Species |
Human |
Protein Construction |
sFASR/TNFRSF6 (Arg17-Asn173) Accession # P25445 |
|
Purity |
> 95% as analyzed by SDS-PAGE > 95% as analyzed by HPLC |
Endotoxin Level |
< 1 EU/μg of protein by LAL method |
Biological Activity |
Fully biologically active when compared to standard. The ED50 as determined by its ability to inhibit the cytotoxicity of Jurkat cells is between 10.0-15.0 μg/ml in the presence of 2.0 ng/ml of rHuFas Ligand. |
Expression System |
E. coli |
Theoretical Molecular Weight |
17.6 kDa |
Formulation |
Lyophilized from a 0.2 μm filtered solution in PBS, pH 7.4. |
Reconstitution |
It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/ml. |
Storage & Stability |
Upon receiving, this product remains stable for up to 6 months at -70°C or -20°C. Upon reconstitution, the product should be stable for up to 1 week at 4°C or up to 3 months at -20°C. Avoid repeated freeze-thaw cycles. |
Target Background |
Fas and Fas Ligand (FasL) belong to the TNF superfamily and are type I and type II transmembrane proteins, respectively. Binding of FasL to Fas triggers apoptosis in Fas-bearing cells. The mechanism of apoptosis involves recruitment of pro-caspase 8 through an adaptor molecule called FADD followed by processing of the pro-enzyme to active forms. These active caspases then cleave various cellular substrates leading to the eventual cell death. sFasR is capable of inhibiting FasL-induced apoptosis by acting as a decoy receptor that serves as a sink for FasL. |
Synonyms |
soluble Fas receptor; sFasR; TNFRSF6; CD95; Apo I; Fas Antigen |
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.